Back

Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Practical dilemmas in atrial fibrillation therapies Rhythm Control, Cardioversion ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Michiel Rienstra

University Medical Centre Groningen, Groningen (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
State-of-the art lecture on practical dilemmas in atrial fibrillation therapies
Professor J. Camm (London, GB)
Slides Video
Presentation thumbnail
Postoperative atrial fibrillation following noncardiac surgery is associated with long-term heart failure: insights from a nationwide cohort
Ms M. Karacan (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Strategy optimization for the combined procedure of left atrial appendage occlusion plus catheter ablation in patients with atrial fibrillation (COMBINATION): a multi-center, randomized study
Doctor X. Du (Ningbo, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Practical dilemmas in atrial fibrillation therapies
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources